stockrowWhat it does
Vaxcyte is a clinical-stage biotechnology company developing vaccines against bacterial diseases. It has no products approved for commercial sale. Its candidates are intended for adults and children, with its principal programs targeting pneumococcal disease, an infection that can cause pneumonia, meningitis and other illnesses.
The company uses a cell-free protein synthesis platform called XpressCF to make proteins and antigens used in vaccine candidates. Antigens are components intended to prompt an immune response. Vaxcyte also uses a process that attaches antigens to protein carriers at specified points. The company believes this approach can help it include more bacterial strains in a vaccine without compromising the immune response.
Its lead candidate, VAX-31, is a 31-valent pneumococcal conjugate vaccine: it is designed to target 31 serotypes, or types, of pneumococcal bacteria. Vaxcyte is studying it in adults and infants. VAX-24 is another pneumococcal candidate being developed for infants, while VAX-XL is an earlier-generation program designed to provide broader coverage.
Beyond pneumococcal disease, VAX-A1 is intended to prevent disease caused by Group A Strep, and VAX-GI is a preclinical candidate for Shigella-related illness. Vaxcyte has paused advancement of VAX-GI beyond preclinical development while prioritizing its pneumococcal programs. It also has discovery-stage programs using the same platform.
How it makes money
Vaxcyte has no vaccines approved for commercial sale. It is developing candidates that, if approved, could generate revenue from commercial sales, including potential sales to foreign governments. It has identified product pricing, coverage and reimbursement by third-party payors as factors in commercialization. The available information does not establish a selling price or a recurring revenue stream for its candidates.
The pneumococcal franchise comprises VAX-31, VAX-24 and VAX-XL. VAX-31 is in adult Phase 3 trials and an infant Phase 2 study. VAX-24 has completed an infant Phase 2 study, and Vaxcyte plans an infant Phase 3 program using an optimized formulation of either VAX-24 or VAX-31 after the VAX-31 infant results. VAX-XL is a candidate designed for broader pneumococcal coverage.
VAX-A1 is a Group A Strep vaccine candidate for which the company plans an adult Phase 1 study in 2026. VAX-GI is being developed with the University of Maryland, Baltimore and partial funding from research grants, but its advancement beyond preclinical development is paused.
Vaxcyte has funded operations primarily through securities issuance. From inception through December 31, 2025, it raised approximately $4.7 billion in aggregate gross proceeds. As of December 31, 2025, it had $174.0 million of cash and cash equivalents, $2,268.7 million in investments and an accumulated deficit of $2,154.9 million.
Customers and how it sells
Vaxcyte’s vaccine candidates are intended for adults and children, including infants. Its adult VAX-31 program targets invasive pneumococcal disease and pneumonia; its infant programs target invasive pneumococcal disease. The company has no approved products for commercial sale, so these are intended recipients rather than established product customers.
The company designs its pneumococcal candidates to address strains circulating in the United States and historically prevalent strains. It is also preparing manufacturing arrangements for potential global commercialization. Its commercial opportunity would depend in part on acceptance by the medical community, consumers and third-party payors, as well as pricing and reimbursement.
In the United States, after a vaccine is approved by the FDA, the Advisory Committee on Immunization Practices considers whether to recommend its use. Vaxcyte believes recommendations from that committee and similar international bodies can help drive adoption of its candidates. The company has identified the costs of building a sales force and distribution among its potential commercialization costs.
For its Group A Strep candidate, Vaxcyte plans to begin by studying safety and tolerability in adults. Its Shigella candidate is intended to prevent dysentery and shigellosis.
Suppliers and costs
Vaxcyte relies on outside manufacturing partners for its pneumococcal vaccine candidates. Lonza performs process development and clinical manufacturing, including production of components such as antigens, protein carrier and conjugated drug substances. Under a 2026 agreement, Lonza will also perform process development and commercial manufacture and supply of certain key components. Vaxcyte pays for services, certain raw materials and other costs, including a daily facility-operation fee for commercial supply.
Vaxcyte has exclusive rights under an agreement with Sutro Biopharma to develop and manufacture cell-free extract, a component of its pneumococcal franchise, independently or through certain third parties. It also has an agreement with Thermo Fisher for commercial fill-finish capacity in Greenville, North Carolina. That initiative represents a long-term U.S. commercial manufacturing commitment of up to $1 billion.
Other potential costs include clinical trials, regulatory approvals, intellectual property protection, manufacturing capacity, marketing, distribution and a sales force. Vaxcyte has identified the inability to obtain alternative sources for single-source vaccine components as a risk. It had 507 employees in FY2025.
Competitive position
Vaxcyte competes with established pneumococcal vaccine makers and companies developing new candidates. Pfizer markets Prevnar products, including PCV20; Merck markets PPSV23, PCV15 and PCV21; and GSK markets Synflorix. These product families generated a combined $8.5 billion in global pneumococcal vaccine sales in 2025, with approximately 77%, 21% and 2%, respectively.
Pfizer is developing a 25-valent candidate and a 30-plus valent preclinical candidate. Merck is advancing additional pneumococcal candidates through early-phase studies. GSK has begun an adult Phase 1 study of a 30-plus valent candidate. Sanofi and SK bioscience are developing a 21-valent candidate in a global pediatric Phase 3 program and a next-generation candidate. In Group A Strep, Moderna has a candidate in a Phase 1 study.
Vaxcyte’s technology includes site-specific conjugation, intended to attach antigens to protein carriers while preserving immune responses. The company also has an exclusive license to patents and patent applications related to XpressCF and patents covering vaccine candidates and processes.
Our reading: The platform and intellectual property could provide a competitive distinction, but the strength of that protection in the market remains unproven because Vaxcyte has no approved product. Our reading: Existing competitors’ marketed vaccines and development programs limit the protection that broader intended strain coverage alone can provide.
| Competitor | Where they compete | Threat (our reading) |
|---|---|---|
| Pfizer | Marketed and next-generation pneumococcal vaccines | High |
| Merck | Marketed and next-generation pneumococcal vaccines | High |
| GSK | Pneumococcal and Group A Strep vaccines | Medium |
| Sanofi | Pediatric and next-generation pneumococcal vaccines | Medium |
| SK bioscience | Pediatric and next-generation pneumococcal vaccines | Medium |
| Moderna | Group A Strep vaccines | Medium |
Growth opportunities
Vaxcyte is pursuing adult and pediatric pneumococcal vaccination as its principal development opportunity. The company sizes the global pneumococcal vaccine market at approximately $8 billion. It designed VAX-31 to cover both currently circulating and historically prevalent serotypes, and believes its candidates could replace current standard-of-care vaccines if approved.
VAX-31 entered its pivotal adult Phase 3 trial, OPUS-1, in December 2025. Vaxcyte expects topline safety, tolerability and immune-response data in the fourth quarter of 2026. It has also initiated adult Phase 3 studies examining use alongside a seasonal influenza vaccine and use in people previously given a lower-valency pneumococcal vaccine. The company expects data from those studies in the first half of 2027.
In infants, Vaxcyte completed enrollment in its VAX-31 Phase 2 study and expects primary-series and booster data by the end of the first half of 2027. After that readout, it plans to begin a Phase 3 infant program with an optimized formulation of VAX-24 or VAX-31. VAX-XL is a further pneumococcal candidate in the pipeline.
Outside pneumococcal disease, Vaxcyte plans a Phase 1 adult study of VAX-A1 in 2026. It also continues discovery-stage work using its cell-free platform, while keeping the option to advance VAX-GI in the future.
Structural risks
- Clinical and regulatory: Candidates may produce negative or inconclusive trial results, adverse effects, or fail to meet immune-response or efficacy endpoints. Regulators may require additional studies or interpret data differently.
- Technology and manufacturing: Vaxcyte’s approach uses unproven technologies. It or its contractors may be unable to scale manufacturing, secure sufficient components or meet regulatory requirements for clinical and commercial supply.
- Capital needs: Trials, manufacturing, approvals and commercialization require funding. Vaxcyte may need additional capital and may be unable to raise it on acceptable terms or continue a program if development is delayed.
- Commercial adoption: Even if approved, candidates depend on pricing, coverage, reimbursement, clinical recommendations and acceptance by physicians, patients and payors.
- Competition: Other vaccines may be approved and launched first. Competitors may offer products that are safer, more effective, more convenient, less expensive or have a more favorable label.
- Intellectual property and suppliers: Vaxcyte must maintain and protect its intellectual property and has identified the inability to find alternatives for single-source components as a risk.
Bottom line
Our reading
Our reading: Vaxcyte is a vaccine developer whose business depends on turning clinical candidates into approved products, rather than on established product sales. Its opportunity rests on pneumococcal coverage and its manufacturing technology, while trial results, regulatory approval, scale-up and competition from established vaccine makers remain central uncertainties. Its cash and investments provide resources for development, but future capital needs depend on the cost and progress of its programs.